These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8745399)

  • 61. Comparative molecular modeling analysis of-5-amidinoindole and benzamidine binding to thrombin and trypsin: specific H-bond formation contributes to high 5-amidinoindole potency and selectivity for thrombin and factor Xa.
    Zhou Y; Johnson ME
    J Mol Recognit; 1999; 12(4):235-41. PubMed ID: 10440994
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hydrophobic affinity chromatography of human thrombin.
    Lundblad RL; Tsai J; Wu HF; Jenzano JW; White GC; Connolly TM
    Arch Biochem Biophys; 1993 Apr; 302(1):109-12. PubMed ID: 8470887
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Proton bridging in the interactions of thrombin with small inhibitors.
    Kovach IM; Kelley P; Eddy C; Jordan F; Baykal A
    Biochemistry; 2009 Aug; 48(30):7296-304. PubMed ID: 19530705
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inhibition of trypsin and thrombin by amino(4-amidinophenyl)methanephosphonate diphenyl ester derivatives: X-ray structures and molecular models.
    Bertrand JA; Oleksyszyn J; Kam CM; Boduszek B; Presnell S; Plaskon RR; Suddath FL; Powers JC; Williams LD
    Biochemistry; 1996 Mar; 35(10):3147-55. PubMed ID: 8605148
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Functionality map analysis of the active site cleft of human thrombin.
    Grootenhuis PD; Karplus M
    J Comput Aided Mol Des; 1996 Feb; 10(1):1-10. PubMed ID: 8786410
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures.
    Slon-Usakiewicz JJ; Sivaraman J; Li Y; Cygler M; Konishi Y
    Biochemistry; 2000 Mar; 39(9):2384-91. PubMed ID: 10694407
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Active-site-selective labeling of blood coagulation proteinases with fluorescence probes by the use of thioester peptide chloromethyl ketones. II. Properties of thrombin derivatives as reporters of prothrombin fragment 2 binding and specificity of the labeling approach for other proteinases.
    Bock PE
    J Biol Chem; 1992 Jul; 267(21):14974-81. PubMed ID: 1634536
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene.
    Rubens FD; Weitz JI; Brash JL; Kinlough-Rathbone RL
    Thromb Haemost; 1993 Feb; 69(2):130-4. PubMed ID: 8456425
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Novel non-covalent thrombin inhibitors incorporating P(1) 4,5,6,7-tetrahydrobenzothiazole arginine side chain mimetics.
    Marinko P; Krbavcic A; Mlinsek G; Solmajer T; Bakija AT; Stegnar M; Stojan J; Kikelj D
    Eur J Med Chem; 2004 Mar; 39(3):257-65. PubMed ID: 15051174
    [TBL] [Abstract][Full Text] [Related]  

  • 70. PPACK-thrombin is a noncompetitive inhibitor of alpha-thrombin binding to human platelets.
    Schmaier AH; Meloni FJ; Nawarawong W; Jiang YP
    Thromb Res; 1992 Sep; 67(5):479-89. PubMed ID: 1448784
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The Na+ binding site of thrombin.
    Di Cera E; Guinto ER; Vindigni A; Dang QD; Ayala YM; Wuyi M; Tulinsky A
    J Biol Chem; 1995 Sep; 270(38):22089-92. PubMed ID: 7673182
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Structure of the Ser195Ala mutant of human alpha--thrombin complexed with fibrinopeptide A(7--16): evidence for residual catalytic activity.
    Krishnan R; Sadler JE; Tulinsky A
    Acta Crystallogr D Biol Crystallogr; 2000 Apr; 56(Pt 4):406-10. PubMed ID: 10739913
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin-inhibitor complexes.
    Obst U; Banner DW; Weber L; Diederich F
    Chem Biol; 1997 Apr; 4(4):287-95. PubMed ID: 9195869
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment.
    Bode W; Mayr I; Baumann U; Huber R; Stone SR; Hofsteenge J
    EMBO J; 1989 Nov; 8(11):3467-75. PubMed ID: 2583108
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Protease inhibitors. Part 2. Weakly basic thrombin inhibitors incorporating sulfonyl-aminoguanidine moieties as S1 anchoring groups: synthesis and structure-activity correlations.
    Clare BW; Scozzafava A; Briganti F; Iorga B; Supuran CT
    J Enzyme Inhib; 2000; 15(3):235-64. PubMed ID: 10811030
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Crystal structure of thrombin in a self-inhibited conformation.
    Pineda AO; Chen ZW; Bah A; Garvey LC; Mathews FS; Di Cera E
    J Biol Chem; 2006 Oct; 281(43):32922-8. PubMed ID: 16954215
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immobilization of the irreversible thrombin inhibitor D-Phe-Pro-Arg-chloromethylketone: a concept for hemocompatible surfaces?
    Maitz MF; Sperling C; Werner C
    J Biomed Mater Res A; 2010 Sep; 94(3):905-12. PubMed ID: 20730927
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug design.
    Engh RA; Brandstetter H; Sucher G; Eichinger A; Baumann U; Bode W; Huber R; Poll T; Rudolph R; von der Saal W
    Structure; 1996 Nov; 4(11):1353-62. PubMed ID: 8939759
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Geometry of binding of the N alpha-tosylated piperidides of m-amidino-, p-amidino- and p-guanidino phenylalanine to thrombin and trypsin. X-ray crystal structures of their trypsin complexes and modeling of their thrombin complexes.
    Turk D; Stürzebecher J; Bode W
    FEBS Lett; 1991 Aug; 287(1-2):133-8. PubMed ID: 1879520
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket.
    Pineda AO; Chen ZW; Caccia S; Cantwell AM; Savvides SN; Waksman G; Mathews FS; Di Cera E
    J Biol Chem; 2004 Sep; 279(38):39824-8. PubMed ID: 15252033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.